Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded down 1.6% on Tuesday . The company traded as low as $2.10 and last traded at $2.21. 302,693 shares were traded during trading, a decline of 62% from the average session volume of 803,860 shares. The stock had previously closed at $2.18.
Separately, Chardan Capital decreased their price objective on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a report on Thursday, August 10th.
The company’s market capitalization is $151.08 million. The firm’s 50 day moving average price is $1.58 and its 200 day moving average price is $1.47.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its earnings results on Wednesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.01). The company had revenue of $27.62 million for the quarter, compared to analysts’ expectations of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The company’s quarterly revenue was up 119.6% compared to the same quarter last year. During the same period last year, the business earned ($0.27) EPS. Equities research analysts forecast that Aralez Pharmaceuticals Inc. will post ($1.62) earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in ARLZ. KCG Holdings Inc. purchased a new position in Aralez Pharmaceuticals during the first quarter worth about $310,000. Broadfin Capital LLC boosted its stake in Aralez Pharmaceuticals by 8.3% during the first quarter. Broadfin Capital LLC now owns 5,191,590 shares of the company’s stock worth $11,110,000 after buying an additional 400,000 shares during the period. FNY Managed Accounts LLC boosted its stake in Aralez Pharmaceuticals by 4.2% during the first quarter. FNY Managed Accounts LLC now owns 77,119 shares of the company’s stock worth $165,000 after buying an additional 3,136 shares during the period. Goldman Sachs Group Inc. boosted its stake in Aralez Pharmaceuticals by 0.3% during the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock worth $260,000 after buying an additional 354 shares during the period. Finally, Franklin Street Advisors Inc. NC boosted its stake in Aralez Pharmaceuticals by 67.5% during the second quarter. Franklin Street Advisors Inc. NC now owns 99,229 shares of the company’s stock worth $134,000 after buying an additional 40,000 shares during the period. 23.79% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Aralez Pharmaceuticals Inc. (ARLZ) Trading Down 1.6%” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/10/10/aralez-pharmaceuticals-inc-arlz-trading-down-1-6.html.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
What are top analysts saying about Aralez Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aralez Pharmaceuticals Inc. and related companies.